ReviewSeminars in fetal & neonatal medicine2021
When to say no to inhaled nitric oxide in neonates?
Review in Seminars in fetal & neonatal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Circulating Endothelial Nitric Oxide Synthase on the First Postpartum Day: An Exploratory Cross-Sectional Study of Its Association with Maternal Age, Redox-Relevant Haematological and Lipid Markers, and Postnatal Depression Screening.Antioxidants (Basel, Switzerland) · 2026Article
- Management of Hypoxemic Respiratory Failure in the Newborn During Therapeutic Hypothermia.Clinics in perinatology · 2026Review
- Respiratory trajectory and risk of death or moderate-to-severe bronchopulmonary dysplasia in very preterm infants: a nine-year cohort study.Frontiers in pediatrics · 2026Article
- ExploringDiagnostics (Basel, Switzerland) · 2025Article
- Current and Emerging Therapies for Prevention and Treatment of Bronchopulmonary Dysplasia in Preterm Infants.Paediatric drugs · 2025Review
- Sound Waves Versus Pressure Waves: The Increasing Role of Echocardiography and Noninvasive Vasoreactivity Testing in Pediatric Pulmonary Hypertension Management.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- Clinical Analysis of Inhaled Nitric Oxide Therapy in Preterm Infants at Different Gestational Ages: A National Retrospective Multicenter Study.American journal of perinatology · 2025Article
- Cardiorespiratory interactions during the transitional period in extremely preterm infants: a narrative review.Pediatric research · 2025Review
- Risk factors, incidence, and outcomes of neonatal respiratory extracorporeal membrane oxygenation including association with therapeutic hypothermia in California during 2013-2020.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- Pulmonary hypertension in the newborn- etiology and pathogenesis.Seminars in fetal & neonatal medicine · 2022Review
- Simple and sensitive nitric oxide biosensor based on the electrocatalysis of horseradish peroxidase on AuNPs@metal-organic framework composite-modified electrode.Mikrochimica acta · 2022Article
- Factors to Consider to Study Preductal Oxygen Saturation Targets in Neonatal Pulmonary Hypertension.Children (Basel, Switzerland) · 2022Review
- Neonatal and Postneonatal Pulmonary Hypertension.Children (Basel, Switzerland) · 2021Article
- [Recent research on inhaled nitric oxide in preterm infants with a gestational age of <34 weeks].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Inhaled nitric oxide (iNO) was approved for use in critically ill term and near-term neonates (>34 weeks gestational age) in 1999 for hypoxic respiratory failure (HRF) with evidence of pulmonary hypertension. In 2011 and 2014, the National Institutes of Health and American Academy of Pediatrics respectively recommended against the use of iNO in preterm infants <34 weeks. However, these guidelines were based on trials conducted with varying inclusion criteria and outcomes. Recent guidelines from the American Thoracic Society/American Heart Association, the Pediatric Pulmonary Hypertension Network (PPHNet) and European Pediatric Pulmonary Vascular Disease Network recommend the use of iNO in preterm neonates with HRF with confirmed pulmonary hypertension. This review discusses the available evidence for off-label use of iNO. Preterm infants with prolonged rupture of membranes and pulmonary hypoplasia appear to respond to iNO. Similarly, preterm infants with physiology of pulmonary hypertension with extrapulmonary right-to-left shunts may potentially have an oxygenation response to iNO. An overview of relative and absolute contraindications for iNO use in neonates is provided. Absolute contraindications to iNO use include a ductal dependent congenital heart disease where systemic circulation is supported by a right-to-left ductal shunt, severe left ventricular dysfunction and severe congenital methemoglobinemia. In preterm infants, we do not recommend the routine use of iNO in HRF due to parenchymal lung disease without pulmonary hypertension and prophylactic use to prevent bronchopulmonary dysplasia. Future randomized trials evaluating iNO in preterm infants with pulmonary hypertension and/or pulmonary hypoplasia are warranted. (233/250 words).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.